NVO Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of -253.13%. Novo Nordisk A/S's return on equity of 62.44% beat Cellectis SA's return on equity of -65.19%.

Novo Nordisk A/S has a consensus price target of $47.36, signalling upside risk potential of 28.08%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 112.61%. Given that Cellectis SA has higher upside potential than Novo Nordisk A/S, analysts believe Cellectis SA is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.726, which suggesting that the stock is 27.371% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.653%.

Novo Nordisk A/S has a quarterly dividend of $1.22 per share corresponding to a yield of 4.81%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 36.87% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Cellectis SA quarterly revenues of $10.4M. Novo Nordisk A/S's net income of $4.2B is higher than Cellectis SA's net income of -$26.3M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 10.66x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.52x versus 4.70x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 62.44% beat DBV Technologies SA's return on equity of -217.87%.

Novo Nordisk A/S has a consensus price target of $47.36, signalling upside risk potential of 28.08%. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that DBV Technologies SA has higher upside potential than Novo Nordisk A/S, analysts believe DBV Technologies SA is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.726, which suggesting that the stock is 27.371% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.

Novo Nordisk A/S has a quarterly dividend of $1.22 per share corresponding to a yield of 4.81%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 36.87% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than DBV Technologies SA quarterly revenues of --. Novo Nordisk A/S's net income of $4.2B is higher than DBV Technologies SA's net income of -$44.8M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 10.66x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.52x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of -64.14%. Novo Nordisk A/S's return on equity of 62.44% beat Evaxion AS's return on equity of -80.26%.

Novo Nordisk A/S has a consensus price target of $47.36, signalling upside risk potential of 28.08%. On the other hand Evaxion AS has an analysts' consensus of $11.25 which suggests that it could grow by 197.62%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.726, which suggesting that the stock is 27.371% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.187, suggesting its less volatile than the S&P 500 by 81.283%.

Novo Nordisk A/S has a quarterly dividend of $1.22 per share corresponding to a yield of 4.81%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 36.87% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Evaxion AS quarterly revenues of --. Novo Nordisk A/S's net income of $4.2B is higher than Evaxion AS's net income of -$5.9M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 10.66x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.52x versus 3.13x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 62.44% beat Viking Therapeutics, Inc.'s return on equity of -46.41%.

Novo Nordisk A/S has a consensus price target of $47.36, signalling upside risk potential of 28.08%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $92.72 which suggests that it could grow by 166.44%. Given that Viking Therapeutics, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Viking Therapeutics, Inc. is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.726, which suggesting that the stock is 27.371% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.689%.

Novo Nordisk A/S has a quarterly dividend of $1.22 per share corresponding to a yield of 4.81%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 36.87% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Novo Nordisk A/S's net income of $4.2B is higher than Viking Therapeutics, Inc.'s net income of -$157.7M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 10.66x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.52x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.